Can Thyroid Problems Be Misdiagnosed as IBS? The Overlooked Hormonal Connection

Yes, thyroid problems can be misdiagnosed as IBS, and it happens more often than most patients realize. The reason is straightforward: thyroid dysfunction causes constipation, diarrhea, bloating, and abdominal pain through direct effects on gut motility, and these symptoms overlap almost completely with IBS. The issue is not that the connection is unknown. It is that TSH testing is not consistently included in the GI workup, so the thyroid never gets checked.

Why Does the Thyroid Get Missed in GI Workups?

IBS is diagnosed using the Rome IV criteria, which are symptom-based. A patient needs to have recurrent abdominal pain at least one day per week for the last three months, associated with defecation, a change in stool frequency, or a change in stool form. The criteria state that symptoms should not be explained by another structural or biochemical abnormality, but they do not mandate a specific list of tests. The workup is left to clinical judgment.

In practice, a standard IBS evaluation often includes a complete blood count, basic metabolic panel, C-reactive protein or erythrocyte sedimentation rate, celiac serology, and sometimes a colonoscopy in patients over 45 or with alarm features. TSH is sometimes included, but not always. A 2019 survey of gastroenterologists found significant variation in the tests ordered for suspected IBS, with thyroid function testing far from universal (Lacy et al., 2019). If the initial workup comes back clean and the patient meets Rome criteria, the IBS label gets applied.

Another factor is presentation bias. When a patient presents to a gastroenterologist specifically for gut symptoms, the clinical focus naturally narrows to GI causes. Thyroid dysfunction is considered an endocrine problem, and unless the patient mentions fatigue, weight changes, or temperature sensitivity (or the clinician asks), the thyroid may not enter the differential diagnosis.

Subclinical Hypothyroidism: The Diagnostic Gray Zone

Subclinical hypothyroidism is defined as an elevated TSH (typically 4.5-10 mIU/L) with a normal free T4 level. It affects 4-10% of the adult population, making it remarkably common (Biondi & Cooper, 2008). The clinical significance is debated. Some patients with subclinical hypothyroidism report symptoms including constipation, fatigue, and cognitive slowing. Others feel entirely fine.

From a GI perspective, the question is whether a mildly elevated TSH produces enough motility impairment to cause IBS-like symptoms. The honest answer is that we do not have strong evidence either way. Studies on gut motility in subclinical hypothyroidism are limited and have produced mixed results. What is clear is that overt hypothyroidism (TSH above 10, low free T4) reliably slows gut transit. The subclinical range remains genuinely uncertain.

This uncertainty has practical consequences. A patient with a TSH of 6.5, normal free T4, and chronic constipation may be told their thyroid is 'fine' by one doctor and 'borderline' by another. If they also meet Rome IV criteria for IBS-C, the IBS diagnosis may stick even though mild thyroid dysfunction could be contributing. Some endocrinologists advocate a trial of low-dose levothyroxine in symptomatic subclinical hypothyroidism, but guidelines vary by country and professional society.

The Thyroid-Gut Axis: A Two-Way Street

The relationship between the thyroid and the gut is not one-directional. Thyroid hormones regulate gut motility and function, but the gut also plays a role in thyroid hormone metabolism. Approximately 20% of T4-to-T3 conversion (the activation of thyroid hormone) occurs in the gastrointestinal tract, facilitated by intestinal deiodinase enzymes and influenced by the gut microbiome (Knezevic et al., 2020).

This bidirectional relationship means that gut dysfunction can worsen thyroid function, and thyroid dysfunction can worsen gut problems, creating a feedback loop. A patient with Hashimoto's who develops SIBO may find that their thyroid medication becomes less effective (because SIBO impairs absorption and T4-to-T3 conversion), which further slows their gut motility, which worsens the SIBO. Breaking the cycle requires addressing both ends of the axis.

The gut microbiome itself appears to influence thyroid function. Animal studies and early human data suggest that certain gut bacteria affect thyroid hormone levels through mechanisms including enterohepatic cycling of thyroid hormones and modulation of iodine uptake (Virili & Centanni, 2017). This research is still in its early stages, but it reinforces the concept that gut health and thyroid health are linked.

Hashimoto's and SIBO: A High-Risk Combination

Hashimoto's thyroiditis, the autoimmune form of hypothyroidism, deserves special attention in the IBS misdiagnosis context. A 2007 study by Lauritano and colleagues found SIBO in approximately 54% of hypothyroid patients on breath testing, compared to single-digit rates in healthy controls (Lauritano et al., 2007). The hypothyroidism-SIBO connection is driven primarily by reduced gut motility: when the migrating motor complex slows down, bacteria accumulate in the small intestine.

But Hashimoto's may add additional risk beyond the motility effect. As an autoimmune condition, Hashimoto's is associated with increased intestinal permeability and immune dysregulation that could independently affect the gut microbiome. Hashimoto's also clusters with celiac disease at 2-5 times expected rates (Ch'ng et al., 2007), meaning a patient with Hashimoto's and gut symptoms could have thyroid-driven motility problems, SIBO, celiac disease, or a combination of all three. Each requires different testing and different treatment.

Can Levothyroxine Itself Cause GI Symptoms?

Here is a complication that many patients do not expect: the medication used to treat hypothyroidism can itself cause digestive symptoms. Levothyroxine, the standard treatment for hypothyroidism, lists nausea, abdominal cramps, and diarrhea among its potential side effects, particularly during dose adjustments or if the dose is too high. Some patients also report bloating and changes in bowel habits after starting treatment.

Levothyroxine absorption is highly sensitive to the GI environment. The medication must be taken on an empty stomach, typically 30-60 minutes before breakfast, because food reduces absorption by 20-40%. Calcium supplements, iron supplements, antacids, and proton pump inhibitors also impair absorption (Centanni et al., 2006). If a patient takes levothyroxine with breakfast or alongside other medications, absorption becomes erratic, leading to fluctuating hormone levels that can produce alternating constipation and diarrhea.

This creates a diagnostic challenge. A hypothyroid patient who develops GI symptoms after starting levothyroxine could be experiencing: medication side effects from an incorrect dose, continued hypothyroid symptoms from an inadequate dose, SIBO that developed during the hypothyroid period and persists, or true co-occurring IBS. Sorting out the cause requires careful attention to timing, dose adjustments, and potentially additional testing.

What Should Change in the IBS Workup?

The practical fix is straightforward: include TSH in the initial workup for IBS-like symptoms. It is a single, inexpensive blood test that can identify or rule out thyroid dysfunction. Several professional guidelines already suggest it. The American Gastroenterological Association's 2022 update on IBS-C management notes that thyroid function testing is reasonable in the evaluation of constipation-predominant patients. But 'reasonable' is not the same as 'required,' and in busy clinical practice, tests that are not mandated are sometimes omitted.

For patients with autoimmune thyroid disease, the workup should be broader. TSH alone is not enough. Thyroid antibodies (TPO, thyroglobulin), celiac serology, and consideration of SIBO breath testing are all warranted when Hashimoto's or Graves' is present alongside persistent GI symptoms.